Artemin stimulates oncogenicity and invasiveness of human endometrial carcinoma cells

Endocrinology

Volumn 151, Issue 3, 2010, Pages 909-920

  Pandey, Vijay ^a   Qian, Peng Xu ^c   Kang, Jian ^a   Perry, Jo K ^a   Mitchell, Murray D ^a   Yin, Zhinan ^d   Wu, Zheng Sheng ^e   Liu, Dong Xu ^a   Zhu, Tao ^c   Lobie, Peter E ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^d NANKAI UNIVERSITY   (China)

^e ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMIN; SMALL INTERFERING RNA;

ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER SIZE; CARCINOGENICITY; CELL COUNT; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; CARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MYOMETRIUM; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NERVE TISSUE PROTEINS; PHENOTYPE;

EID: 77149168759     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2009-0979     Document Type: Article

References (49)

1. Kitchener H 2006 Management of endometrial cancer. Eur J Surg Oncol 32:838-843
2. Hecht JL, Mutter GL 2006 Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 24:4783-4791
3. Ibáñez CF 1998 Emerging themes in structural biology of neurotrophic factors. Trends Neurosci 21:438-444
4. Baloh RH, Gorodinsky A, Golden JP, Tansey MG, Keck CL, Popescu NC, Johnson Jr EM, Milbrandt J 1998 GFRα3 is an orphan member of the GDNF/neurturin/persephin receptor family. Proc Natl Acad Sci USA 95:5801-5806
5. Worby CA, Vega QC, Chao HH, Seasholtz AF, Thompson RC, Dixon JE 1998 Identification and characterization of GFRα-3, a novel co-receptor belonging to the glial cell line-derived neurotrophic receptor family. J Biol Chem 273:3502-3508
6. Bespalov MM, Saarma M 2007 GDNF family receptor complexes are emerging drug targets. Trends Pharmacol Sci 28:68-74
7. Poteryaev D, Titievsky A, Sun YF, Thomas-Crusells J, Lindahl M, Billaud M, Arumaë U, Saarma M 1999 GDNF triggers a novel ret-independent Src kinase family-coupled signaling via a GPI-linked GDNF receptor α1. FEBS Lett 463:63-66
8. Kang J, Perry JK, Pandey V, Fielder GC, Mei B, Qian PX, Wu ZS, Zhu T, Liu DX, Lobie PE 2009 Artemin is oncogenic for human mammary carcinoma cells. Oncogene 28:2034-2045
9. Ceyhan GO, Giese NA, Erkan M, Kerscher AG, Wente MN, Giese T, Büchler MW, Friess H 2006 The neurotrophic factor artemin promotes pancreatic cancer invasion. Ann Surg 244:274-281
10. Ito Y, Okada Y, Sato M, Sawai H, Funahashi H, Murase T, Hayakawa T, Manabe T 2005 Expression of glial cell line-derived neurotrophic factor family members and their receptors in pancreatic cancers. Surgery 138:788-794
11. Esseghir S, Reis-Filho JS, Kennedy A, James M, O'Hare MJ, Jeffery R, Poulsom R, Isacke CM 2006 Identification of transmembrane proteins as potential prognostic markers and therapeutic targets in breast cancer by a screen for signal sequence encoding transcripts. J Pathol 210:420-430
12. Esseghir S, Todd SK, Hunt T, Poulsom R, Plaza-Menacho I, Reis-Filho JS, Isacke CM 2007 A role for glial cell derived neurotrophic factor induced expression by inflammatory cytokines andRET/GFR α1 receptor up-regulation in breast cancer. Cancer Res 67:11732-11741
13. Castellone MD, Santoro M 2008 Dysregulated RET signaling in thyroid cancer. Endocrinol Metab Clin North Am 37:363-374, viii
14. Runeberg-Roos P, Saarma M 2007 Neurotrophic factor receptor RET: structure, cell biology, and inherited diseases. Ann Med 39: 572-580
15. Pandey V, Perry JK, Mohankumar KM, Kong XJ, Liu SM, Wu ZS, Mitchell MD, Zhu T, Lobie PE 2008 Autocrine human growth hormone stimulates oncogenicity of endometrial carcinoma cells. Endocrinology 149:3909-3919
16. Rahnama F, Shafiei F, Gluckman PD, Mitchell MD, Lobie PE 2006 Epigenetic regulation of human trophoblastic cell migration and invasion. Endocrinology 147:5275-5283
17. Masure S, Haefner B, Wesselink JJ, Hoefnagel E, Mortier E, Verhasselt P, Tuytelaars A, Gordon R, Richardson A 1999 Molecular cloning, expression and characterization of the human serine/threonine kinase Akt-3. Eur J Biochem/FEBS 265:353-360
18. Zhu T, Starling-Emerald B, Zhang X, Lee KO, Gluckman PD, Mertani HC, Lobie PE 2005 Oncogenic transformation of human mammary epithelial cells by autocrine human growth hormone. Cancer Res 65:317-324
19. Horrée N, van Diest PJ, van der Groep P, Sie-Go DM, Heintz AP 2008 Progressive derailment of cell cycle regulators in endometrial carcinogenesis. J Clin Pathol 61:36-42
20. Ray D, Kiyokawa H 2008 CDC25A phosphatase: a rate-limiting oncogene that determines genomic stability. Cancer Res 68:1251-1253
21. Lee J, Sung YH, Cheong C, Choi YS, Jeon HK, Sun W, Hahn WC, Ishikawa F, Lee HW 2008 TERT promotes cellular and organismal survival independently of telomerase activity. Oncogene 27:3754-3760
22. Evan G, Littlewood T 1998 A matter of life and cell death. Science 281:1317-1322
23. Hanahan D, Weinberg RA 2000 The hallmarks of cancer. Cell 100: 57-70
24. Thiery JP 2002 Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442-454
25. Kato S, Espinoza N, Lange S, Villalón M, Cuello M, Owen GI 2008 Characterization and phenotypic variation with passage number of cultured human endometrial adenocarcinoma cells. Tissue Cell 40: 95-102
26. Lang SH, Hyde C, Reid IN, Hitchcock IS, Hart CA, Bryden AA, Villette JM, Stower MJ, Maitland NJ 2002 Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma. Prostate 52:253-263
27. Steelman LS, Stadelman KM, Chappell WH, Horn S, Bäsecke J, Cervello M, Nicoletti F, Libra M, Stivala F, Martelli AM, McCubrey JA 2008 Akt as a therapeutic target in cancer. Expert Opin Ther Targets 12:1139-1165
28. Temkin SM, Fleming G 2009 Current treatment of metastatic endometrial cancer. Cancer Control 16:38-45
29. Milde-Langosch K, Riethdorf S 2003 Role of cell-cycle regulatory proteins in gynecological cancer. J Cell Physiol 196:224-244
30. Nikaido T, Li SF, Shiozawa T, Fujii S 1996 Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas. Cancer 78:1248-1253
31. Frenzel A, Grespi F, Chmelewskij W, Villunger A 2009 Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis 14:584-596
32. Geisler JP, Geisler HE, Wiemann MC, Zhou Z, Miller GA, Crabtree W 1998 Lack of bcl-2 persistence: an independent prognostic indicator of poor prognosis in endometrial carcinoma. Gynecol Oncol 71:305-307
33. Marone M, Ferrandina G, Macchia G, Mozzetti S, de Pasqua A, Benedetti-Panici P, Mancuso S, Scambia G 2000 Bcl-2, Bax, Bcl-x(L) and Bcl-x(S) expression in neoplastic and normal endometrium. Oncology 58:161-168
34. Chen ML, Xu PZ, Peng XD, Chen WS, Guzman G, Yang X, Di Cristofano A, Pandolfi PP, Hay N 2006 The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes Dev 20:1569-1574
35. Uegaki K, Kanamori Y, Kigawa J, Kawaguchi W, Kaneko R, Naniwa J, Takahashi M, Shimada M, Oishi T, Itamochi H, Terakawa N 2005 PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma. Oncol Rep 14:389-392
36. Jin X, Gossett DR, Wang S, Yang D, Cao Y, Chen J, Guo R, Reynolds RK, Lin J 2004 Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells. Br J Cancer 91:1808-1812
37. Gagnon V, Mathieu I, Sexton E, Leblanc K, Asselin E 2004 AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol 94:785-795
38. Schütte A, Yan Q, Mestres P, Giehl KM 2000 The endogenous survival promotion of axotomized rat corticospinal neurons by brain-derived neurotrophic factor is mediated via paracrine, rather than autocrine mechanisms. Neurosci Lett 290:185-188
39. Veit C, Genze F, Menke A, Hoeffert S, Gress TM, Gierschik P, Giehl K 2004 Activation of phosphatidylinositol 3-kinase and extracellular signal-regulated kinase is required for glial cell line-derived neurotrophic factor-induced migration and invasion of pancreatic carcinoma cells. Cancer Res 64:5291-5300
40. Okada Y, Eibl G, Duffy JP, Reber HA, Hines OJ 2003 Glial cell-derived neurotrophic factor upregulates the expression and activation of matrix metalloproteinase-9 in human pancreatic cancer. Surgery 134:293-299
41. Honda H, Barrueto FF, Gogusev J, Im DD, Morin PJ 2008 Serial analysis of gene expression reveals differential expression between endometriosis and normal endometrium. Possible roles forAXLand SHC1 in the pathogenesis of endometriosis. Reprod Biol Endocrinol 6:59
42. Monaghan H, MacWhinnie N, Williams AR 2007 The role of matrix metalloproteinases-2, -7 and -9 and β-catenin in high grade endometrial carcinoma. Histopathology 50:348-357
43. Steiner E, Pollow K, Hasenclever D, Schormann W, Hermes M, Schmidt M, Puhl A, Brulport M, BauerA, Petry IB, Koelbl H, Hengstler JG 2008 Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type1(PAI-1) for prognosis in endometrial cancer. Gynecol Oncol 108:569-576
44. Kyo S, Sakaguchi J, Ohno S, Mizumoto Y, Maida Y, Hashimoto M, Nakamura M, Takakura M, Nakajima M, Masutomi K, Inoue M 2006 High Twist expression is involved in infiltrative endometrial cancer and affects patient survival. Hum Pathol 37:431-438
45. Larue L, Bellacosa A 2005 Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene 24:7443-7454
46. Park TW, Zivanovic O, Theuerkauf I, Dürkop B, Hernando JJ, Simon M, Büttner R, Kuhn W 2004 The diagnostic utility of human papillomavirus-testing in combination with immunohistochemistry in advanced gynaecologic pelvic tumours: a new diagnostic approach. Int J Oncol 24:829-836
47. Bansal N, Yendluri V, Wenham RM 2009 The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 16:8-13
48. Treeck O, Diedrich K, Ortmann O 2003 The activation of an extracellular signal-regulated kinase by oestradiol interferes with the effects of trastuzumab on HER2 signalling in endometrial adenocarcinoma cell lines. Eur J Cancer 39:1302-1309
49. Kim EM, Lobocki C, Dubay L, Mittal VK 2009 A specific vascular endothelial growth factor receptor tyrosine kinase inhibitor enhances the antiproliferative effect of trastuzumab in human epidermal growth factor receptor 2 overexpressing breast cancer cell lines. Am J Surg 197:331-336